WIN 65579

Drug Profile

WIN 65579

Alternative Names: SR 265579

Latest Information Update: 08 Aug 2007

Price : $50

At a glance

  • Originator Sanofi-Synthelabo
  • Developer Chinoin; Sanofi Winthrop; Sanofi-Synthelabo
  • Class Bronchodilators
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Cardiovascular disorders

Most Recent Events

  • 27 Jan 2000 A preclinical study has been added to the Obstructive Airways Disease pharmacodynamics section
  • 31 Dec 1999 Preclinical development for Asthma in Hungary (PO)
  • 31 Dec 1999 Preclinical development for Asthma in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top